Why the study?
The authors sought to analyse plasma levels of peripheral blood microRNAs as biomarkers of STEMI due to type-1 myocardial infarction as a model of vulnerable plaque rupture.
Do plasma levels of miR-331 and miR-151-3p distinguish patients with STEMI from those with stable coronary artery disease or no coronary atherosclerosis?
Do plasma levels of miR-331 and miR-151-3p distinguish patients with STEMI from those with stable coronary artery disease or no coronary atherosclerosis?
Plasma levels of miR-331 and miR-151-3p may serve as novel, early biomarkers for STEMI associated with vulnerable plaque rupture, detectable before standard necrosis markers.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for early miRNA biomarkers in STEMI; prospective validation required before clinical adoption.
We sought to analyse plasma levels of peripheral blood microRNAs (miRs) as biomarkers of ST-segment-elevation myocardial infarction (STEMI) due to type-1 myocardial infarction as a model situation of vulnerable plaque (VP) rupture. Samples of 20 patients with STEMI were compared both with a group of patients without angina pectoris in whom coronary angiogram did not reveal coronary atherosclerotic disease (no coronary atherosclerosis-NCA) and a group of patients with stable angina pectoris and at least one significant coronary artery stenosis (stable coronary artery disease-SCAD). This study design allowed us to identify miRs deregulated in the setting of acute coronary artery occlusion due to VP rupture. Based on an initial large scale miR assay screening, we selected a total of 12 miRs (three study miRs and nine controls) that were tested in the study. Two of the study miRs (miR-331 and miR-151-3p) significantly distinguished STEMI patients from the control groups, while ROC analysis confirmed their suitability as biomarkers. Importantly, this was observed in patients presenting early with STEMI, even before the markers of myocardial necrosis (cardiac troponin I, miR-208 and miR-499) were elevated, which suggests that the origin of miR-331 and miR-151-3p might be in the VP. In conclusion, the study provides two novel biomarkers observed in STEMI, which may be associated with plaque rupture.
No takes yet. Share an insight, caveat, or question.
Horváth et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: